Zobrazeno 1 - 10
of 3 353
pro vyhledávání: ''
Autor:
Ashish Panigrahi, Constantine S. Tam, Piers Blombery, Xiangting Chen, John F. Seymour, Dennis A. Carney, Andrew H. Wei, Thomas E Lew, Mary Ann Anderson, Andrew W. Roberts, Ella R. Thompson, David C. S. Huang, Tamia Nguyen, David Westerman, Michael A. Dengler, Victor S Lin, Sasanka M. Handunnetti, Jerry M. Adams
Publikováno v:
Blood. 139:1198-1207
The BCL2 inhibitor venetoclax has established therapeutic roles in chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). As BCL2 is an important determinant of survival of both myeloid progenitor and B cells, we investigated whether cl
Autor:
Ben Barron-Millar, Andrew L. Mellor, Henrique Lemos, John D. Isaacs, Nicola J. Maney, Christopher D. Carey, Amy E. Anderson, Ian Herron, Arthur G. Pratt
Publikováno v:
Arthritis & Rheumatology. 73:1820-1830
Objective As well as being an established oncoprotein and therapeutic target in cancer, proviral integration site for Moloney murine leukemia virus 1 (Pim-1) is implicated in human autoimmunity. This study was undertaken to investigate Pim-1 and its
Autor:
Christelle Le Dantec, Cristina Adela Iuga, Ioana-Ecaterina Pralea, Melanie Cornen, Wesley H. Brooks, Jacques-Olivier Pers, Hussam Saad, Tiffany Bergot, Adrian Tempescul, Anne Bordron, Delphine G. Bernard, Jean-Christophe Ianotto, Cristina Bagacean, Mihnea Zdrenghea, Christian Berthou, Yves Renaudineau
Publikováno v:
Journal of Leukocyte Biology
Journal of Leukocyte Biology, 2022, 111 (2), pp.313-325. ⟨10.1002/JLB.4HI0620-392R⟩
Journal of Leukocyte Biology, 2022, 111 (2), pp.313-325. ⟨10.1002/JLB.4HI0620-392R⟩
Chronic lymphocytic leukemia (CLL) is characterized by significant biologic and clinical heterogeneity. This study was designed to explore CLL B-cells’ proteomic profile in order to identify biologic processes affected at an early stage and during
Autor:
Laurence Kraus-Berthier, Lucie Laplane, Véronique Saada, Céline Berthon, Maria E. Figueroa, Bouchra Badaoui, Margaux Sevin, Franck Debeurme, Eric Padron, Thorsten Braun, Qin Yang, Nathalie Droin, Raphael Itzykson, Guido Kroemer, Dorothée Selimoglu-Buet, Eric Solary, Oliver Kepp, Margot Morabito, Alix Derreal, Hannah Newman, Sylvain Thepot, Gabriel Etienne, Miguel Torres-Martin, Sébastien Banquet, Severine Badel, Orianne Wagner-Ballon, Pierre Fenaux
Publikováno v:
Blood
Blood, American Society of Hematology, 2021, 137 (24), pp.3390-3402. ⟨10.1182/blood.2020008729⟩
Blood, American Society of Hematology, 2021, 137 (24), pp.3390-3402. ⟨10.1182/blood.2020008729⟩
Mouse models of chronic myeloid malignancies suggest that targeting mature cells of the malignant clone disrupts feedback loops that promote disease expansion. Here, we show that in chronic myelomonocytic leukemia (CMML), monocytes that accumulate in
Autor:
Jan Budczies, Cornelius F. Waller, Amanda Tufman, Martina Kirchner, Torsten Goldmann, Albrecht Stenzinger, Peter Schirmacher, Petros Christopoulos, Michael Meister, Mark Kriegsmann, Michael Thomas, Martin Reck, Solange Peters, Klaus Kluck, Hauke Winter, Julia Glade, Daniel Kazdal, Stefan Fröhling, Michael Allgäuer, Thomas Muley, Felix J.F. Herth, CP Heußel, Martin Wermke
Publikováno v:
Cancer Immunology, Immunotherapy
Introduction The advent of immune checkpoint blockade (ICB) has led to significantly improved disease outcome in lung adenocarcinoma (ADC), but response of ALK/EGFR-positive tumors to immune therapy is limited. The underlying immune biology is incomp
Autor:
Tao Wang, Helen E. Heslop, Stephen Gottschalk, Bambi Grilley, Rammurti T. Kamble, Carlos A. Ramos, Ann M. Leen, Meng-Fen Wu, Malcolm K. Brenner, Robert A. Krance, Catherine Robertson, Manik Kuvalekar, Jasleen K. Randhawa, Spyridoula Vasileiou, Adrian P. Gee, Suhasini Lulla, Juan F. Vera, Betty Chung, Ayumi Watanabe, Premal Lulla, Ifigeneia Tzannou, Swati Naik, LaQuisa Hill, George Carrum
Publikováno v:
Blood
Relapse after allogeneic hematopoietic stem cell transplantation (HCT) is the leading cause of death in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Infusion of unselected donor lymphocytes (DLIs) enhances the graft-v
Autor:
Ulrich Jaeger, Marek Borsky, Jan Oppelt, Laura Z. Rassenti, Medhat Shehata, Václav Šeda, Thomas J. Kipps, Gabriela Pavlasova, Jennifer R. Brown, Daniel Filip, Kvetoslava Liskova, Šárka Pospíšilová, Eva Vojackova, Lenka Kostalova, Matthew S. Davids, Marek Mráz, Katerina Cerna, Sonali Sharma, Jiri Mayer, Andrea Janíková, Pedro Faria Zeni, Stacey M. Fernandes, Veronika Šandová, Laura Ondrisova, Michael Doubek, Leos Kren
Publikováno v:
Blood
B-cell receptor (BCR) signaling and T-cell interactions play a pivotal role in chronic lymphocytic leukemia (CLL) pathogenesis and disease aggressiveness. CLL cells can use microRNAs (miRNAs) and their targets to modulate microenvironmental interacti
Autor:
Nan Yang, Wanggang Zhang, Xu-Geng Wang, Yang Zhang, Hui Zhang, Jin Wang, Huan Yao, Shan Meng, Yueli Wang, Hailing Liu, Ting Wang, She-Ping Chen, Jinqiu Chen, Bo Lei
Publikováno v:
Immunotherapy. 13:571-585
Aim: This study explored new immunoadjuvants with stronger immune activity to enhance therapeutic effects against leukemia. Materials & methods: Whole blood and bone marrow of acute myeloid leukemia (AML) patients and healthy volunteers were collecte
Autor:
Panpan Han, Jun Peng, Guosheng Li, Yu Hou, Yang Liu, Haoyi Wang, Yunqi Sun, Tianshu Yu, Hai Zhou, Ming Hou, Xinguang Liu, Lizhen Li, Yajing Zhao, Pengcheng Xu, Xiang Hu, Tao Sun
Publikováno v:
Blood. 138:674-688
Our previous clinical study showed that low-dose decitabine exhibited sustained responses in nearly half of patients with refractory immune thrombocytopenia (ITP). The long-term efficacy of decitabine in ITP is not likely due to its simple role in in
Autor:
Isabelle S. Csete, Ross L. Levine, Qi Gao, Alexander Chan, Andriy Derkach, Maximilian Stahl, Sheng F. Cai, Jinjuan Yao, Tanmay Mishra, Richard Koche, Sophia Yanis, Martin S. Tallman, Aaron D Goldberg, Michael R. Waarts, Raajit K. Rampal, Ahmet Dogan, Robert L. Bowman, Minal Patel, Ying Liu, Wenbin Xiao, Mikhail Roshal, Maria E. Arcila, Jeeyeon Baik, Nicole L. DelGaudio, Christopher Famulare, Yanming Zhang
Publikováno v:
Blood
Plasmacytoid dendritic cells (pDCs) are the principal natural type I interferon–producing dendritic cells. Neoplastic expansion of pDCs and pDC precursors leads to blastic plasmacytoid dendritic cell neoplasm (BPDCN), and clonal expansion of mature